All In Biotech

Free tool

FAERS Monitor: Vigafyde

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217684 or its brand name (Vigafyde, Vigabatrin). Reports on generic versions are filed under their own applications.

Reports

4,764

Serious

3,805

80% of reports

Hospitalization

1,774

Death reported

453

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • seizure938
  • drug ineffective709
  • off label use372
  • hospitalisation315
  • death253
  • adverse event247
  • somnolence197
  • epilepsy191
  • multiple-drug resistance178
  • magnetic resonance imaging head abnormal167
  • drug resistance162
  • vomiting161
  • product use issue152
  • status epilepticus152
  • condition aggravated151

Reports by year received

View as table
YearReports
20048
200515
200617
200710
200850
200927
201019
201122
201227
201356
201446
201546
201651
201772
2018236
2019309
2020399
2021439
2022540
2023581
2024685
2025665
2026444

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,395 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
magnetic resonance imaging head abnormalSignal1671530.91286.8188,493
multiple-drug resistanceSignal178268.8231.744,520
status epilepticusSignal15260.251.58,681
seizureSignal93836.134.131,928
drug resistanceSignal16228.024.14,172
epilepsySignal19127.724.14,875
adverse eventSignal24711.910.52,450
hospitalisationSignal3159.18.12,265
somnolenceSignal1974.33.8504
product use issueSignal1523.63.1281
drug ineffectiveSignal7092.42.2601
condition aggravatedSignal1512.21.998
off label use3721.91.7158
vomiting1611.51.328
death2531.31.218

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.